BVXV - BiondVax Pharmaceuticals Ltd.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
6.11
+0.05 (+0.83%)
At close: 3:55PM EST
Stock chart is not supported by your current browser
Previous Close6.06
Open6.10
Bid6.05 x 200
Ask7.84 x 900
Day's Range6.10 - 6.24
52 Week Range4.60 - 10.75
Volume3,812
Avg. Volume18,509
Market Cap1.597B
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference
    PR Newswire9 days ago

    BiondVax and European UNISEC Consortium to Host Universal Flu Vaccine Conference

    NESS ZIONA, Israel, Feb. 8, 2018 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (BVXV), developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting, which will take place next week in Jerusalem, Israel. Attendees representing the consortium's partners from academia, government, and industry will discuss achievements towards development of a universal influenza vaccine, including the recent successful results of the Phase 2b clinical trial on BiondVax's universal flu vaccine candidate M-001. Also expected to attend will be representatives from the U.S. Department of Health and Human Services (HHS).

  • BiondVax Universal Flu Vaccine Patent Granted in India
    PR Newswire2 months ago

    BiondVax Universal Flu Vaccine Patent Granted in India

    NESS ZIONA, Israel, Jan. 2, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV), developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, announced today that one of its key patents titled "A Synthetic or Recombinant Influenza Multi-Epitope Polypeptide" has been granted in India. The patent belongs to BiondVax's portfolio family titled "Multimeric Multi-Epitope Influenza Vaccines" and has now been granted in over 30 countries. With a population of over 1.3 billion people, and high population density in some of the major cities, India is an important potential market for BiondVax and a universal flu vaccine may significantly improve public health.

  • BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)
    PR Newswire2 months ago

    BiondVax Plans Phase 3 Clinical Trial Following Receipt of Scientific Advice from the European Medicines Agency (EMA)

    NESS ZIONA, Israel, Dec. 27, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV) announced today that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) reviewed BiondVax's Phase 3 trial plan, provided advice, and allowed the Company to proceed with the Phase 3 clinical trial plan for M-001, BiondVax's universal flu vaccine candidate. Babecoff continued, "There is a clear need to improve upon current flu vaccine technologies, as noted in the recent New England Journal of Medicine article titled Chasing Seasonal Influenza — The Need for a Universal Influenza Vaccine.[1]  BiondVax's Universal Flu Vaccine candidate is designed to address challenges of current flu vaccines such as mismatches, mutations, and long production lag.

  • Zacks Small Cap Research2 months ago

    BVXV: Planning Continues for M-001 Phase 3 Program …

    BiondVax’s (BVXV) strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has already initiated discussions with the European Medicines Agency (EMA) regarding the trial design. The trial is being conducted in Eastern Europe since there are not recommendations in some of those countries to get the yearly influenza vaccine, thus making it much easier to enroll sufficient numbers of subjects who have not been previously immunized with the yearly influenza vaccine.

  • ACCESSWIRE2 months ago

    Blog Exposure - Synlogic And Ginkgo Bioworks Collaborate to Discover and Develop New Medicines for Neurological and Liver Disorders

    Stock Monitor: BiondVax Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 11, 2017 / Active-Investors issued a free report on Synlogic, Inc. (NASDAQ: SYBX ), which is readily accessible ...

  • BiondVax's CEO Issues Letter to Shareholders
    PR Newswire2 months ago

    BiondVax's CEO Issues Letter to Shareholders

    NESS ZIONA, Israel , Dec. 5, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today released a Letter from the CEO regarding recent activities and plans. "BiondVax has ...

  • PR Newswire3 months ago

    BiondVax Provides Third Quarter 2017 Financial Results and Update

    NESS ZIONA, Israel , Nov. 28, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, ...

  • PR Newswire3 months ago

    BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The study is titled "A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity, and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Trivalent Influenza Vaccine." It is designed to evaluate the cell mediated immunity directly induced by BiondVax's universal flu vaccine candidate M-001, as well as M-001's priming effect to enhance the immunogenicity of current seasonal influenza vaccines.

  • Zacks Small Cap Research5 months ago

    BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine

    As expected, the company did not report any revenues during the quarter. The company reported a net loss of $3.5 million for the second quarter of 2017, which was comprised of $0.6 million in R&D expenses and $0.2 million in G&A expenses. On September 19, 2017, the company announced the closing of a public offering of 1.5 million American Depository Shares (ADS) for $6.00 per ADS.

  • PR Newswire5 months ago

    BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has closed an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. In connection with the public offering, the underwriters exercised in full their over-allotment option to purchase an additional 166,667 shares of common stock at the public offering price, less the underwriting discount. As a result, the total public offering size was 1,666,667 shares, and the gross proceeds from the public offering were $10 million, before deducting underwriting discounts and offering expenses.

  • PR Newswire5 months ago

    BiondVax Announces Pricing of Public Offering of American Depositary Shares

    NESS ZIONA, Israel, Sept. 13, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has priced an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. BiondVax Pharmaceuticals has granted the underwriter a 45-day option to purchase up to 166,667 additional ADS. The ADSs described above will be issued pursuant to a registration statement on Form F-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on December 15, 2016.

  • PR Newswire5 months ago

    BiondVax Announces Public Offering of American Depositary Shares

    BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares ("ADS"), each representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each). All of the ADSs in the offering are being offered by BiondVax. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.

  • Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?
    Simply Wall St.5 months ago

    Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?

    BiondVax Pharmaceuticals Ltd (NASDAQ:BVXV), a pharmaceuticals, biotechnology and life sciences company based in Israel, See our latest analysis for BVXV What’s the opportunity in BVXV? Great news for investors –Read More...

  • ACCESSWIRE5 months ago

    Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates

    Research Desk Line-up: BiondVax Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • PR Newswire6 months ago

    Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange

    BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), developer of the universal flu vaccine candidate M-001, today announced that its Board of Directors has decided to voluntarily delist from the Tel Aviv Stock Exchange (TASE), while maintaining a continued listing on NASDAQ. Following the European Investment Bank (EIB)'s significant €20 million funding agreement[1], and as BiondVax progresses towards Phase 3 clinical trials[2] and construction of its commercial mid-size manufacturing facility[3], the Board of Directors decided that BiondVax will focus its efforts on the international scene.

  • PR Newswire6 months ago

    BiondVax Provides Second Quarter 2017 Financial Results and Update

    NESS ZIONA, Israel , Aug. 31, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, ...

  • PR Newswire6 months ago

    BiondVax Receives Additional Grant Funding

    Israel Innovation Authority Approves Additional Budget towards M-001 Flu Vaccine Development NESS ZIONA, Israel , August 14, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) (TASE: BVXV) ...

  • Zacks Small Cap Research7 months ago

    BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine

    On July 20, 2017, BiondVax Pharmaceuticals, Ltd. announced results from the company’s Phase 2b clinical trial of M-001, the universal influenza vaccine candidate. The trial, which was funded through a grant from the European Union and was conducted in conjunction with the European UNISEC Consortium, enrolled a total of 219 participants aged 18 to 60 years. The trial hit both primary endpoints for safety and immunological response.

  • PR Newswire7 months ago

    BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine

    European UNISEC Co-Sponsored Trial Meets Both Primary Endpoints NESS ZIONA, Israel , July 20, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), and the UNISEC consortium today ...

  • PR Newswire7 months ago

    BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today signed an agreement to lease approximately 1800m2 in the Jerusalem BioPark (JBP), located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University's Medical School. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Planning and design of the facility by a leading engineering company has begun, and while construction will begin soon, the agreement calls for BiondVax to begin lease payments in October 2018.

  • Zacks Small Cap Research7 months ago

    BVXV: Secures $22 Million Loan Agreement with European Investment Bank…

    On June 19, 2017, BiondVax Pharmaceuticals, Ltd. (BVXV) announced it entered into a $22 million (€20 million) loan agreement with the European Investment Bank (EIB). The loan is a part of Horizon 2020, which is a research and innovation program established by the EU with over €80 billion of funding available over 7 years (2014-2020). The goal of Horizon 2020 is to drive economic growth and create jobs, while allowing innovative firms the chance to access capital more easily.

  • PR Newswire8 months ago

    BiondVax's CEO Provides First Half 2017 General Corporate Update

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today provided a general corporate update of its activities in the first half of 2017. Ron Babecoff, BiondVax CEO, commented, "The first half of 2017 was exciting and important for BiondVax.

  • PR Newswire8 months ago

    European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative

    The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a €20 million (approximately $22 million) loan agreement. The event organized to mark the collaboration and the granting of the loan occurs today at the EIB Headquarters in Luxembourg, in presence of Mr. Ambroise Fayolle, EIB Vice-President responsible for innovation, and Dr. Ron Babecoff, CEO of BiondVax. Flu viruses frequently and unpredictably mutate.

  • Accesswire8 months ago

    Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials

    Research Desk Line-up: BiondVax Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for The ...

  • Zacks Small Cap Research9 months ago

    BVXV: Immunogenicity Results From Phase 2b Trial of M-001 Expected Soon…

    An investment such as this is important as it shows a level of confidence in both M-001 and the BiondVax management team as well as providing the company with much needed capital to continue development of M-001 into Phase 3 clinical trials. On March 13, 2017, BiondVax Pharmaceuticals Ltd. (BVXV) announced the publication of an article written by BiondVax-affiliated authors titled, “Strategy for approving a universal flu vaccine” in the journal Future Virology (Ben-Yedidia et al., 2017). Currently, the efficacy of all seasonal influenza vaccines is tested based on induction of hemagglutination inhibition (HAI) antibodies that target the outer variable regions of the viral hemagglutinin protein.